Andrew oversees process development as well as preclinical plasmid and viral vector production at Andelyn Biosciences. He leads a diverse organization of interdisciplinary scientists specializing in high throughput manufacturing as well as process development, optimization and scale-up of production platforms to offer solutions to clients for accelerating gene therapy products to the patients who need them.

Andrew has over two decades of experience in genetic and molecular research with roles at Syngenta and The Ohio State University. He joined Nationwide Children's Hospital and now Andelyn in 2007 focusing on the production and development of gene therapy products. He has a B.S. in Biology from Purdue University.